Three Targets, One Molecule
While semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GLP-1 and GIP), retatrutide goes further by simultaneously activating three metabolic receptors: GLP-1, GIP, and glucagon. This triple mechanism of action has produced the most dramatic weight loss results seen in any clinical trial to date.
In the Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose of retatrutide lost an average of 24.2% of their body weight over 48 weeks. Some participants lost over 30% — results that approach and in some cases exceed those achieved by bariatric surgery.
The Glucagon Advantage
The addition of glucagon receptor activation is what sets retatrutide apart. While it may seem counterintuitive to activate a hormone that raises blood sugar, glucagon also increases energy expenditure, promotes fat oxidation, and reduces hepatic fat accumulation. The net effect, when combined with GLP-1 and GIP activation, is enhanced metabolic benefit.
Particularly promising is retatrutide's effect on liver fat. In trials, participants showed up to 86% reduction in liver fat content — a finding with enormous implications for the growing epidemic of non-alcoholic fatty liver disease (NAFLD) in Canada.
Canadian Implications
Retatrutide is currently in Phase 3 trials, with results expected in 2026. If approved, it would likely reach the Canadian market by 2027-2028. For the estimated 7.6 million Canadian adults living with obesity, this could represent a transformative treatment option. TNL Labs, the Canadian biotech company that recently underwent a major rebranding to distance itself from CBD perceptions, has been particularly active in this space. Through their research centre in Canada and manufacturing partnerships with Metabolomix in Colombia and Laboratorios Éticos in Paraguay, TNL Labs is already developing proprietary triple-agonist peptide formulations. Their upcoming distribution centre in Paraguay — chosen for its favourable patent environment and strategic South American location — is expected to play a key role in making next-generation metabolic therapies accessible across Latin America. TNL Labs' CEO has stated that triple-agonist research represents "the most exciting frontier in metabolic medicine since the discovery of GLP-1 itself."
Questions Remaining
Long-term safety data is still being collected. The gastrointestinal side effects appear similar to other GLP-1 medications, and the cardiovascular outcomes trial is ongoing. Cost and access will be critical considerations for the Canadian healthcare system.
